Catrin Treharne recently joined Mtech Access as a Director in our Health Economics team. In this interview, she tells us about her experiences and activities in her first few weeks...
Read More
In this webinar, we explored the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe. Orphan medicines and rare disease treatments are...
Read More
On World Evidence-Based Healthcare Day (20th October 2021), Shona Lang (Senior Consultant -Evidence Synthesis), Stephanie Swift (Consultant - Evidence Synthesis) and Calum Jones (Consultant Health Economist) explore the role of...
Read More
To celebrate World Patient Safety Day 2021, Dr Stephanie Swift and Dr Shona Lang, Consultant and Senior Consultant in Systematic Reviews and Evidence Synthesis at Mtech Access, highlight some of...
Read More
Finding, bringing together and synthesising a comprehensive evidence base is a key part of the reimbursement process and the wider market access journey for pharmaceutical products. This evidence generation process...
Read More
Janine Ross, who recently joined the Mtech Access evidence team as a Consultant Information Scientist, explains how her aptitude for searching and identifying evidence data has earned her the nickname...
Read More
Last month, our evidence team tuned in to watch the Virtually Cochrane conference. Each year the Cochrane conference explores the latest thought leadership in systematic review and healthcare evidence. This...
Read More
Are you looking to launch a new medical technology, medical or diagnostic device in the UK, Europe or North America? Would you like to know how health economic modelling could...
Read More
James Woolnough (Senior Medical Writer) shares his impressions of attending a virtual committee meeting at the National Institute for Health and Care Excellence (NICE) as a public observer. James is...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In Part 3 of the...
Read More
